

**An Intensive Workshop on Antiretroviral Strategies:
New Drugs, Antiretroviral Failure, and Resistance Testing**



Seattle, WA

Friday, May 29, 2009

Registration opens: 12:30 PM *

Workshop: 1:00 PM – 4:30 PM

Talaris Conference Center
Maple Room
4000 NE 41st St.
Seattle, WA 98105

* Lunch is included in the Registration Fee and will be served in the main dining room from 11:45 AM - 12:30 PM.

This workshop is sponsored by the International AIDS Society-USA and is offered in collaboration with the Northwest AIDS Education and Training Center.

Workshop Faculty

Eric S. Daar, MD

Professor of Medicine
David Geffen School of Medicine at UCLA
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Los Angeles, CA

Joel E. Gallant, MD, MPH

Professor of Medicine and Epidemiology
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Associate Director
Johns Hopkins AIDS Service
Baltimore, MD

Local Host

David H. Spach, MD

Medical Director
Northwest AIDS Education and Training Center
Professor of Medicine
University of Washington

Who Should Attend

Experienced HIV clinical decision makers (physicians, nurse practitioners, physician assistants) caring for HIV patients with a working knowledge of HIV disease management.

Overview and Assessment of Needs

Expert faculty will speak in a small-group interactive setting on timely and clinically relevant issues in HIV disease management such as:

- Management strategies for antiretroviral failure
- Role of resistance testing to determine treatment options for patients with multiple drug resistance mutations
- Role of new drugs in failure regimens

Rapid advances in these areas require the ongoing attention of practitioners involved in HIV medicine. The course will address the implications of this information on strategies for antiretroviral therapy.

CME Accreditation Statement

The International AIDS Society–USA is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

Credit Designation Statement

The International AIDS Society–USA designates this educational activity for a maximum of 3.25 *AMA PRA Category 1 Credits*.™ Physicians should only claim credit commensurate with the extent of their participation in the activity.

Learning Objectives

Upon completion of the workshop, participants will be able to:

- Design appropriate treatment strategies for patients experiencing antiretroviral failure that consider current data on new drugs, new classes, and new assays
- Identify the elements of an effective salvage regimen
- Compare and contrast the benefits and limitations of genotypes and phenotypes
- Explain the effective use of tropism assays and how they may fit into the management of HIV-infected patients
- Examine the risk and activity and the resistance profiles of new and emerging antiretroviral drugs

Registration

The registration fee is \$30. Fax or mail your complete registration form (below) with payment. Registration closes May 22, 2009. Registrations will be accepted on a first-come, first-served basis. Attendance is limited to 35 participants. Forms should be mailed or faxed to:

International AIDS Society-USA
425 California Street, Suite 1450
San Francisco, CA 94104-2120
Tel: 415-544-9400
Fax: 415-544-9402

Conflicts of Interest

Information regarding conflicts of interest is obtained from all parties with control over the activity content (ie, Board of Directors, workshop development committee, workshop leaders, and IAS-USA staff), and any conflicts of interest of those parties are resolved prior to the activity being delivered.

Funding

This activity is made possible by educational grants from several commercial companies that are committed to supporting independent CME in the field of HIV/AIDS. Major grant support has been provided by: Bristol-Myers Squibb, Pfizer Global Pharmaceuticals, and Merck & Co., Inc.

+ + +

Workshop participant name: _____
(Optional) **CFLS SEA 5.29.09**

**An Intensive Workshop on Antiretroviral Strategies:
New Drugs, Antiretroviral Failure, and Resistance Testing**

Workshop registrants are encouraged to submit their own difficult clinical cases for potential inclusion in the workshop discussion, using the form below. Please complete the form below, include resistance test results, and submit via email (tnichol@iasusa.org) or fax (415-544-9401).

Date of patient review: _____

Resistance test: genotype, phenotype, pheno GT Date of Test: _____

ARV treatment when tested: _____

Adherence assessment: Score: ____ Excellent, Good, Fair, Poor Date: _____

Most recent viral load: ____ Date: ____ Most recent CD4+: ____ Date: _____

Viral load before ARV: ____ Date: ____ Highest viral load recorded: ____ Date: _____

Lowest CD4+: ____ Date: ____ ARV history: high confidence, low confidence

Past Resistance Tests: 1) _____ 2) _____ 3) _____

Past Detected Mutations: NRTI: _____

NNRTI: _____ PI: _____

ARV past history	Date started...ended	Reason discontinued
Regimen 1: _____;	_____;	_____
Regimen 2: _____;	_____;	_____
Regimen 3: _____;	_____;	_____
Regimen 4: _____;	_____;	_____
Regimen 5: _____;	_____;	_____
Regimen 6: _____;	_____;	_____
Regimen 7: _____;	_____;	_____
Regimen 8: _____;	_____;	_____

Exposure to: (circle all that apply)

NRTIs: abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine, zidovudine

NNRTIs: delavirdine, efavirenz, nevirapine, etravirine

PIs: amprenavir, atazanavir, indinavir, fosamprenavir, lopinavir/ritonavir, nelfinavir, ritonavir, saquinavir, tipranavir

Fixed-dose combinations: abacavir/lamivudine, emtricitabine/tenofovir, lamivudine/zidovudine, lamivudine/zidovudine/abacavir, tenofovir/emtricitabine/efavirenz

Fusion inhibitor: enfuvirtide

CCR5 inhibitor: maraviroc

Integrase inhibitor: raltegravir

Confounders (circle): neuropathy, pancreatitis, dyslipidemia, elevated lft's, lipoatrophy, CNS symptoms, hyperlactatemia, lactate acidosis, depression, anemia, neutropenia, TB, HBV, HCV

Other: _____

Allergy history: _____

ARV drug intolerance: _____

Patient refuses: _____

Recommendation: _____

Next clinic visit: _____ Next retro visit: _____



**An Intensive Workshop on Antiretroviral Failure:
New Drugs, Antiretroviral Failure, and Resistance Testing**

Friday, May 29, 2009

Talaris Conference Center
4000 NE 41st St.
Seattle, WA 98105

Registration opens: 12:30 PM
Workshop: 1:00 PM - 4:30 PM

First Name MI Last Name

Title/Position

Institution/Organization

Registration is limited to up to 35 HIV clinical decision makers
(physicians, physician assistants, nurse practitioners).

Primary Academic Degree: ___ MD ___ NP ___ DO ___ PA

Specialty

Mailing Address Work Home

City State Zip

Phone Work Home Fax Work Home

E-Mail Address (for registration confirmation only)

Do you work for a commercial company? Yes No

If Yes, Name of Company: _____

Currently, how many HIV-infected patients do you have? _____

How many years have you been involved in HIV Care? _____

REGISTRATION FEES

Full payment must accompany this form. For additional registrants, please photocopy this form. Cancellations will be accepted until the Registration Deadline, however a processing fee will apply.

\$30 \$ _____

If you wish to include a donation please indicate here* \$ _____

Total: \$ _____

*IAS-USA is exempt from tax under section 501(c)(3) of the Internal Revenue Code. Your tax-deductible donation will be used to distribute *Topics in HIV Medicine*® internationally.

Lunch is included in Fee and will be served from 11:45-12:30 (main dining room).

Special Assistance Needs (please specify): _____

Registration Deadline: Friday, May 22, 2009

Make checks or money orders payable to: **International AIDS Society-USA.**

Charge to my credit card: VISA Mastercard American Express

Card Number (VISA, Mastercard, or AMEX) Exp Date

Authorized Signature on Card

Name on Card

Please mail or fax this registration form and payment to:

International AIDS Society-USA
Registration CFLS
425 California Street, Suite 1450
San Francisco, CA 94104-2120
Phone (415) 544-9400; FAX (415) 544-9402